Literature DB >> 8173360

Tetrahydroaminoacridine and Alzheimer's disease.

E J Byrne, T Arie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8173360      PMCID： PMC2539823          DOI： 10.1136/bmj.308.6933.868

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

1.  Functional imaging procedures in dementias: mapping of EEG and evoked potentials.

Authors:  K Maurer; T Dierks
Journal:  Acta Neurol Scand Suppl       Date:  1992

2.  Tacrine in Alzheimer's disease.

Authors:  S A Eagger; R Levy; B J Sahakian
Journal:  Lancet       Date:  1991-04-27       Impact factor: 79.321

3.  Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly.

Authors:  R H Perry; D Irving; G Blessed; A Fairbairn; E K Perry
Journal:  J Neurol Sci       Date:  1990-02       Impact factor: 3.181

4.  Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial.

Authors:  N Maltby; G A Broe; H Creasey; A F Jorm; H Christensen; W S Brooks
Journal:  BMJ       Date:  1994-04-02

5.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

6.  An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.

Authors:  G K Wilcock; D J Surmon; M Scott; M Boyle; K Mulligan; K A Neubauer; D O'Neill; V H Royston
Journal:  Age Ageing       Date:  1993-09       Impact factor: 10.668

Review 7.  Subtypes of Alzheimer's dementia: a conceptual analysis and critical review.

Authors:  A F Jorm
Journal:  Psychol Med       Date:  1985-08       Impact factor: 7.723

8.  A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

Authors:  K L Davis; L J Thal; E R Gamzu; C S Davis; R F Woolson; S I Gracon; D A Drachman; L S Schneider; P J Whitehouse; T M Hoover
Journal:  N Engl J Med       Date:  1992-10-29       Impact factor: 91.245

9.  A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.

Authors:  M Farlow; S I Gracon; L A Hershey; K W Lewis; C H Sadowsky; J Dolan-Ureno
Journal:  JAMA       Date:  1992-11-11       Impact factor: 56.272

Review 10.  Tetrahydroaminoacridine (THA) in Alzheimer's disease.

Authors:  J Byrne; T Arie
Journal:  BMJ       Date:  1989-04-01
  10 in total
  6 in total

Review 1.  Psychotropic drugs, aging and community care.

Authors:  M Philpot; A Puranik
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

2.  Tacrine and lecithin in Alzheimer's disease. Negative conclusions not justified.

Authors:  G K Wilcock
Journal:  BMJ       Date:  1994-06-04

3.  Tacrine and lecithin in Alzheimer's disease. Patient heterogeneity explains varied response.

Authors:  R Levy
Journal:  BMJ       Date:  1994-06-04

4.  Effects of tacrine upon murine neuroblastoma cells.

Authors:  P Zatta; P Zambenedetti; M B Marturano; M Palumbo; M Nicolini
Journal:  J Neural Transm Gen Sect       Date:  1995

5.  A neurochemical approach for studying response to acetylcholine in Alzheimer's disease.

Authors:  J T Alder; I P Chessell; D M Bowen
Journal:  Neurochem Res       Date:  1995-07       Impact factor: 3.996

6.  Tacrine and lecithin in Alzheimer's disease. Serum tacrine concentrations too low.

Authors:  C Roberts; P Mäkelä; J Ford; C Truman
Journal:  BMJ       Date:  1994-06-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.